ClinicalTrials.gg
WithdrawnNCT01238315Updated Jan 15, 2015

Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis

A Phase 1 interventional study of HuCNS-SC in Neuronal Ceroid Lipofuscinosis, sponsored by StemCells, Inc.. Withdrawn at 1 site in United States. Open to participants aged 6 Months to 6 Years. Per ClinicalTrials.gov, last updated 2015-01-15.

Sponsored by StemCells, Inc. · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Lack of timely patient accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
6 Months to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States — 10 open to participants now, 18 under way, none of them phase 3. Neuronal Ceroid-Lipofuscinoses · United States.

Enrollment
20th of 20
0 · median 11
Started
2010
with 3 others
Phase 1
7 of 38
1 open now
Registered
8th of 38
by date
Lead sponsor
2 of 38
StemCells, Inc.

Among the 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2010, is one of 7 in phase 1, and was the 8th registered.

Neuronal Ceroid-Lipofuscinoses

49 studies on the registry are indexed under Neuronal Ceroid-Lipofuscinoses; 13 are open to participants now.

Browse Neuronal Ceroid-Lipofuscinoses studies →

Open to participants now

10 of the 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Neuronal Ceroid-Lipofuscinoses studies recruiting now, 7 (64%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 2 take healthy volunteers.

This study: 6 Months to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase Ib study is to determine if "Human Central Nervous System Stem Cells"(HuCNS-SC) is safe to be transplanted in subjects with infantile and late infantile neuronal ceroid lipofuscinosis. The study will also measure post-transplantation disease progression.

Read the detailed description

Participation in this study will involve screening assessments, surgery to implant HuCNS-SC, medication to suppress immune system and a series of follow-up assessments.

03

Conditions studied

  • Neuronal Ceroid Lipofuscinosis

Keywords

  • Batten's disease
  • INCL
  • LINCL
  • Neuronal Ceroid Lipofuscinosis
  • NCL
04

Who can participate

Ages eligible
6 Months to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6 months to 6 years
  • Male or female
  • Clinical diagnosis of Infantile neuronal ceroid lipofuscinosis or late infantile neuronal ceroid lipofuscinosis
  • CLN1 or CLN2 mutation

Exclusion criteria

Exclusion Criteria:

  • Previously received an organ, tissue or bone marrow transplantation
  • Previously participated in any gene or cell therapy study
  • Infection with hepatitis virus, cytomegalovirus, Epstein-Barr virus, or (HIV)
  • Current or prior cancer
  • Bleeding disorder
  • Unable to have an MRI scan
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    HuCNS-SC

    Biological: HuCNS-SC

Interventions

  • BiologicalHuCNS-SC

    Surgery to implant human CNS stem cells

    Also known as: human neural stem cells, stem cells, neural stem cells

06

What researchers measure

Primary outcomes

  1. number of participants with adverse events.

    Safety will be measured by number of adverse events and changes in neurological status.

    Time frame: one year following transplantation

Secondary outcomes

  1. Number of subjects with improvement in neurological, neuropsychological development, MRI and MRS

    Time frame: one year following transplantation

07

Study locations

1 site
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2010
First posted
Nov 10, 2010
Start
Nov 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Last update
Jan 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01238315
Lead sponsor
StemCells, Inc.
Responsible party
Sponsor
First posted
Nov 10, 2010
Start date
Nov 2010
Primary completion
Apr 2011
Completion
Apr 2011
Last update
Jan 15, 2015

Study contacts

Nathan Selden, MD, PhD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion